HomeCompareENTO vs PM

ENTO vs PM: Dividend Comparison 2026

ENTO yields 70.18% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTO wins by $1.01M in total portfolio value
10 years
ENTO
ENTO
● Live price
70.18%
Share price
$2.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.06M
Annual income
$278,697.01
Full ENTO calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — ENTO vs PM

📍 ENTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTOPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTO + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENTO pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTO
Annual income on $10K today (after 15% tax)
$5,964.91/yr
After 10yr DRIP, annual income (after tax)
$236,892.46/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, ENTO beats the other by $234,774.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTO + PM for your $10,000?

ENTO: 50%PM: 50%
100% PM50/50100% ENTO
Portfolio after 10yr
$554.8K
Annual income
$140,594.52/yr
Blended yield
25.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ENTO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.6
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTO buys
0
PM buys
0
No recent congressional trades found for ENTO or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTOPM
Forward yield70.18%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$1.06M$49.6K
Annual income after 10y$278,697.01$2,492.02
Total dividends collected$903.3K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ENTO vs PM ($10,000, DRIP)

YearENTO PortfolioENTO Income/yrPM PortfolioPM Income/yrGap
1← crossover$17,718$7,017.54$11,648$408.29+$6.1KENTO
2$30,578$11,619.97$13,589$495.90+$17.0KENTO
3$51,460$18,742.30$15,877$603.21+$35.6KENTO
4$84,541$29,478.65$18,580$734.88+$66.0KENTO
5$135,720$45,260.50$21,781$896.75+$113.9KENTO
6$213,126$67,906.19$25,578$1,096.12+$187.5KENTO
7$327,705$99,659.70$30,092$1,342.17+$297.6KENTO
8$493,857$143,212.72$35,470$1,646.46+$458.4KENTO
9$730,132$201,704.73$41,892$2,023.58+$688.2KENTO
10$1,059,938$278,697.01$49,578$2,492.02+$1.01MENTO

ENTO vs PM: Complete Analysis 2026

ENTOStock

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Full ENTO Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ENTO vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTO vs SCHDENTO vs JEPIENTO vs OENTO vs KOENTO vs MAINENTO vs MOENTO vs BTIENTO vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.